Statement of Changes in Beneficial Ownership (4)
November 13 2019 - 5:00PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Flynn Daniel Lee |
2. Issuer Name and Ticker or Trading Symbol
Deciphera Pharmaceuticals, Inc.
[
DCPH
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Scientific Officer |
(Last)
(First)
(Middle)
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
11/8/2019 |
(Street)
WALTHAM, MA 02451
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 11/8/2019 | | M | | 9742 | A | $1.89 | 34242 | D | |
Common Stock | 11/8/2019 | | S(1) | | 9742 | D | $48.00 | 24500 | D | |
Common Stock | 11/11/2019 | | M | | 143185 | A | $1.89 | 167685 | D | |
Common Stock | 11/11/2019 | | S(1) | | 143185 | D | $48.0139 (2) | 24500 | D | |
Common Stock | | | | | | | | 66779 | I | By Daniel L. Flynn Irrevocable Trust |
Common Stock | | | | | | | | 55270 | I | By Biochenomix, LLC |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $1.89 | 11/8/2019 | | M | | | 9742 | (3) | 12/17/2025 | Common Stock | 9742 | $0.00 | 310009 | D | |
Stock Option (Right to Buy) | $1.89 | 11/11/2019 | | M | | | 143185 | (3) | 12/17/2025 | Common Stock | 143185 | $0.00 | 166824 | D | |
Explanation of Responses: |
(1) | The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
(2) | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.04, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
(3) | This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM, MA 02451 |
|
| Chief Scientific Officer |
|
Signatures
|
/s/ Thomas P. Kelly, Attorney-in-Fact | | 11/13/2019 |
**Signature of Reporting Person | Date |
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024